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By preventing drug access to the central nervous system, the blood-brain barrier 
slows down new discoveries in brain pharmacotherapy. Strong efforts are currently 
made to identify drugs that accumulate more efficaciously in the ischemic brain 
tissue. We identified an ATP-binding cassette transporter, ABCC1, which is 
expressed on the abluminal surface of the brain capillary endothelium and mildly 
downregulated in response to focal cerebral ischemia, induced by intraluminal 
middle cerebral artery occlusion. In biodistribution studies we show that ABCC1 
promotes the accumulation of known neuroprotective and neurotoxic compounds 
in the ischemic and non-ischemic brain, ABCC1 deactivation reducing tissue 
concentrations by up to two orders of magnitude. As such, ABCC1’s expression 
and functionality in the brain differs from the liver, spleen and testis, where ABCC1 
is strongly expressed on parenchymal cells, resulting - in case of liver and testis - 
in a directed transport from the tissue into the blood. After focal cerebral ischemia, 
ABCC1 deactivation abolished the efficacy of both neuroprotective and neurotoxic 
compounds. Our data indicate that ABCC1 acts as gateway for pharmacological 
compounds to the stroke brain. We suggest that the tailoring of compounds 
binding to abluminal but not luminal ATP-binding cassette transporters may 
facilitate stroke pharmacotherapy. 
Keywords: ABC transporter, blood-brain barrier, neuroprotection, 
pharmacotherapy, stroke. 
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Introduction 
Pharmacological therapies have made limited progress in the brain recently 
(Löscher and Potschka, 2005; Hermann et al., 2006). As such, many candidate 
drugs evaluated in clinical trials have failed, particularly in ischemic stroke 
(O’Collins et al., 2006; Hermann and Bassetti, 2007). A major obstacle for newly 
developed compounds is the blood-brain barrier (BBB), which prevents 
systemically administered molecules from entering the brain (Pardridge, 2002; 
Begley, 2004). The BBB acts not only as passive diffusion barrier. It expresses 
active transporters that eliminate drugs from the brain tissue (Löscher and 
Potschka, 2005; Hermann et al., 2006).  
 Strong efforts have been made in recent years to identify pharmacological 
compounds that accumulate more efficaciously in the diseased brain. As such, the 
physicochemical properties of compounds (e.g., lipophilicity, surface charges, 
molecular size), their uptake via receptor-dependent or -independent endocytosis, 
as well as their binding to membrane-bound ATP-binding cassette (ABC) 
transporters and solute carriers were recognized to influence drug accumulation 
(Begley, 2004; Hermann et al., 2006).  
 In contrast to solute carriers, which are bi-directional, low-affinity transporters 
driven by concentration gradients of endogenous molecules (e.g., carnithine, 
urate, Na+, H+), carrying organic compounds through cell membranes both in an 
inward and outward direction (Meier and Stieger, 2002; Hagenbuch and Meier, 
2004), ABC transporters are unidirectional high-affinity pumps eliminating a broad 
variety of chemically unrelated lipophilic and amphipathic molecules from cells in 
an ATP-dependent manner (Higgins et al., 1986; Löscher and Potschka, 2005), 
among which there are many pharmacological compounds. 
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 ABC transporters have received considerable interest in the brain recently, 
since they impede the brain accumulation of drugs. In fact, most ABC transporters, 
such as their best-characterized member ABCB1 (previously called multidrug 
resistance transporter (Mdr)-1), are abundantly expressed on the luminal 
membrane of brain capillary cells (Löscher and Potschka, 2005; Hermann and 
Bassetti, 2007). As a consequence, these transporters extrude drugs from the 
brain back into the blood (Rizzi et al., 2002; Löscher and Potschka, 2005; Spudich 
et al., 2006). 
 Not all ABC transporters exhibit luminal endothelial expression. For the 
transporter ABCC1 (formerly multidrug resistance-associated protein (Mrp)-1), it 
was recently demonstrated that this transporter is predominantly expressed on the 
abluminal endothelial membrane (Soontornmalai et al., 2006). Similar to ABCB1, 
ABCC1 reveals strong binding affinity to many amphipathic compounds (Hermann 
and Bassetti, 2007). Besides, ABCC1 also binds glucuronidated, glutathionized 
and sulfated molecules, which are not ABCB1 substrates (Hermann and Bassetti, 
2007).  
 Until now, the relevancy of ABCC1 for pharmacological therapies remained 
unknown. Using immunohistochemical studies, Western blots with capillary-
enriched brain tissue fractions and experiments, in which we deactivated ABCC1 
by pharmacological inhibition or genetic knockout, we now examined the role of 
ABCC1 in the ischemic brain, analyzing its effect on drug accumulation and 
efficacy after middle cerebral artery (MCA) occlusion. 
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Methods 
Focal cerebral ischemia 
Experiments were performed in accordance to National Institutes of Health (NIH) 
guidelines for the care and use of laboratory animals and approved by local 
government authorities (Kantonales Veterinäramt; ZH169/2005). Male C57Bl6/j 
mice as well as male abcc1-/- mice, produced on a FVB.129P2 background 
(Taconic, New York, USA) together with abcc1+/+ controls, were used. At the age 
of 8-10 weeks (animal weight: 20-23 g), animals were anesthetized with 1% 
isoflurane (30% O2, remainder N2O). Rectal temperature was maintained between 
36.5 and 37.0°C, and laser Doppler flow (LDF) was monitored with a flexible 
fiberoptic probe that was placed above the core of the MCA territory (Perimed, 
Stockholm, Sweden) (Wang et al., 2005; Kilic et al., 2006). Focal cerebral 
ischemia was induced by intraluminal MCA occlusion, as previously described 
(Wang et al., 2005; Kilic et al., 2006). Sham animals received neck incisions, in 
which the common carotid artery was isolated, but not ligated or cut. At indicated 
times (specified below), in case of sham animals after 3 hours reperfusion, 
animals were re-anesthetized and transcardially perfused with normal saline 
(immunohistochemistry/ Western blots; liquid chromatography / mass 
spectrometry [LC-MS] for the ABCC1 substrate 17β-estradiol-17β-D-glucuronide 
[17βEG]) or killed by decapitation (LC-MS for the ABCC1 substrate S-
nitrosoglutathione [GSNO]; drug efficacy studies). Brains, liver, spleen and testis 
were removed, frozen and cut into coronal 18 µm cryostat sections for 
immunohistochemistry of ABC transporters, terminal transferase biotinylated-
dUTP nick end labeling (TUNEL) or cresyl violet staining. Tissue samples were 
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also taken from both MCA territories (lateral parietal cortex and underlying 
striatum), the liver, spleen and testis for Western blots and LC-MS. 
 
Immunohistochemistry for ABCC1 and other multidrug transporters 
Cryostat sections from mice submitted to sham surgery (3 h survival) or to 30 min 
or 90 min of MCA occlusion (3 h reperfusion) (n = 5 animals per group) were fixed 
in 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS), blocked in 0.1 
M PBS containing 0.3% Triton-X-100 (PBS-T) and 10% normal goat serum (NGS) 
and incubated overnight at 4°C with polyclonal guinea pig anti-mouse ABCC1 
(clone J95 ESD8; Institute of Pharmacology and Toxicology, University of Zurich), 
polyclonal rabbit anti-human ABCB1 (H-241, sc-8313; Santa Cruz), polyclonal 
rabbit anti-mouse ABCC2 (clone J81 ESD2; Institute of Pharmacology and 
Toxicology), polyclonal rabbit anti-rat ABCC3 (clone J81 ESD3; Institute of 
Pharmacology and Toxicology) or monoclonal rat anti-human ABCC5 
(ALX801021-C250 or ALX801022-C250; Alexis, Lausen, Switzerland) antibody, 
diluted 1:100 in 0.1 M PBS-T containing 2% NGS. Sections were counterlabeled 
with rat or goat anti-CD31 (BD Biosciences, Basle, Switzerland), mouse anti-NeuN 
(MAB377; Chemicon, Lucerne, Switzerland) or rabbit anti-GFAP (Dako, Zug, 
Switzerland) antibody. The specificity of the ABCC1, ABCB1, ABCC2, ABCC3 and 
ABCC5 antibodies in the brain has previously been shown (Soontornmalai et al., 
2006; Spudich et al., 2006). In fact, negative controls, in which antibodies were 
omitted did not result in any staining (not shown). As positive controls, liver and 
kidney sections were used (Soontornmalai et al., 2006). Sections were evaluated 
microscopically by a blinded investigator. ABCC1 expression levels were 
evaluated by counting densities of ABCC1+ capillaries in a total of six rectangular 
random regions of interest (ROI) in the ischemic and non-ischemic striatum, each 
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1 mm apart, and additional six random ROI in the parietal cortex, 600 µm apart, 
each ROI measuring 62,500 µm2 (Spudich et al., 2006). 
 
Western blots for ABCC1 
Ten µg of enriched microvessel protein (for preparation see Spudich et al., 2006) 
obtained from pooled tissue samples of C57Bl6/j mice submitted to sham surgery 
(3 h survival), 30 min (3, 24 or 72 h reperfusion) or 90 min (3, 12 or 24 h 
reperfusion) of MCA occlusion (n = 5 animals per group) were subjected to sodium 
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred 
onto polyvinylidene fluoride (PVDF) membranes. After blocking, membranes were 
incubated in a monoclonal rat antibody that specifically recognizes ABCC1 
(ALX801007, Alexis; diluted 1:100 in 0.1% TBS-T containing 5% milk). Following 
incubation in peroxidase-coupled secondary antibody, membranes were immersed 
in enhanced chemoluminescence (ECL) solution and exposed to ECL-Hyperfilm 
(Amersham, Otelfingen, Switzerland). Protein loading was controlled with a mouse 
anti-β-actin antibody (Sigma-Aldrich). Blots revealed a ~190 kDa band that was 
absent in control studies in which the primary antibody was omitted. Blots were 
digitized, ABCC1 levels densitometrically analyzed, corrected for protein loading 
and expressed as relative values compared with ABCC1 levels in sham-operated 
mice. 
 
Effects of ABCC1 inhibition on the brain accumulation of 17βEG and GSNO 
 
To evaluate how ABCC1 deactivation affects drug accumulation in the brain, we 
used a pharmacological inhibition strategy using MK571 (Alexis, Lausen, 
Switzerland), a potent ABCC1 blocker (Kimura et al., 2005). Two different ABCC1 
substrates were assessed, namely 17βEG (Sigma-Aldrich) (Cisternino et al., 2003) 
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and GSNO (WPI Europe, Berlin, Germany) (Khan et al., 2005). To evaluate drug 
accumulation in the brain, C57Bl6/j mice submitted to 30 min MCA occlusion were 
treated via the femoral vein with either vehicle (0.9% NaCl) or MK571 (10 mg kg-1 
body weight, dissolved in 0.9% NaCl), 60 min later followed by 17βEG (10 mg kg-1, 
in 0.9% NaCl) (n = 5-7 animals per group) or GSNO (1 mg kg-1, in 0.9% NaCl) (n = 
4 animals per group). Two hours (in case of 17βEG) or 2 min (in case of GSNO) 
later, blood samples were collected in vials coated with lithium heparinate 
(Vacutainer; Becton Dickinson, Basle, Switzerland) and animals were sacrificed. 
The time point of 2 min in case of GSNO was chosen in view of the high instability 
of this NO donor. In a first set of studies, in which animals were killed 15 min or 2 h 
after GSNO infusion, brain levels have been close to or even below detection limits 
(not shown). In the plasma and brain samples obtained, 17βEG, its 
deglucuronidated parent compound 17β-estradiol (17βE) and GSNO were 
analyzed by LC-MS. Similarly, 17βEG and 17βE levels were determined by LC-MS 
in the animals’ liver, spleen and testis. 
 
Liquid chromatography / mass spectrometry (LC-MS) for 17βEG and 17βE 
Weighted tissue samples were homogenized in 0.9% NaCl and divided into 3 
portions as follows: In portion 1, the concentration of 17βE was quantified by the 
addition of 2.5 pmol 17βE-d3 (Sigma-Aldrich) in 50 µl 90% (v/v) ethanol and 50 µl 
phosphate buffer (50 mM, pH 7.0). After extraction with 3 ml dichloromethane, 
separation of the organic phase and evaporation of the solvent, 17βE and 17βE-d3 
in the residue was derivatized by adding 50 µl carbonate buffer (100 mM, pH 10.5) 
and 50 µl dansyl chloride in acetone (1 mg ml-1) for 3 min at 60 °C. After cooling to 
room temperature, the solution was directly injected into the high performance 
liquid chromatography (HPLC) system. In portion 2, the total amount of 17βE and 
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17βEG was quantified by the addition of 2.5 pmol 17βE-d3 in 90% (v/v) ethanol 
and 50 µl (1000 U) β-glucuronidase (Sigma-Aldrich) in phosphate buffer. The 
deglucuronidation was performed for 1 h at 37 °C. In portion 3, 2.5 pmol 17βE in 
50 µl phosphate buffer pH 7.0 and 2.5 pmol 17βEG-d3 in 90% (v/v) ethanol were 
added to enable tissue quantification of 17βE. The extraction and derivatization in 
portion 2 and 3 were identical as described for portion 1. The extraction and 
derivatization of plasma was identical as that for tissue samples. For analysis, 50 
µl plasma were complemented with 2.5 pmol 17βE-d3 in 50 µl 90% (v/v) ethanol, 
50 µl phosphate buffer pH 7.0 and 200 µl 0.9% NaCl.  
The dansylated 17βE was analyzed by the LC-MS / MS system consisting of 
a Rheos 2000 pump (Flux Instruments, Basle, Switzerland), a PAL autosampler 
(CTC Analytics, Zwingen, Switzerland) and a LCQ TSQ 7000 (ThermoQuest, San 
Jose, CA, USA) using selected reaction monitoring. An Uptisphere 5 ODB column 
(125 x 2 mm; Interchim, Montluçon, France) was used. The mobile phase was a 
gradient of water / acetonitrile (95/5, v/v) against water / acetronitrile / methanol 
(5/30/65, v/v) containing 0.1% formic acid. The flow rate was also run as a 
gradient between 0.2 and 0.3 ml min-1. The ionization mode was positive 
atmospheric pressure chemical ionization. The vaporizer temperature and capillary 
temperature were kept at 450 °C and 250 °C, respectively, the discharge current 
fixed at 6 µA. The sheath gas pressure was held at 60 psi, the auxiliary gas 
pressure at 15 psi, respectively. The tissue concentration of 17βE was calculated 
using the standard addition method. Standard curves for 17βE in plasma were 
linear with a correlation coefficient of <0.999 and the coefficients of variations 
<6%. With the concentrations determined, tissue-to-plasma concentration ratios 
were calculated, which were expressed - unless otherwise specified - as pmol g-1 
(tissue) per pmol µl-1 (plasma). 
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LC-MS for GSNO 
Weighted tissue samples were homogenized with 30 mM ammonium sulfamate in 
0.9% NaCl solution containing 0.4% sodium fluoride. To brain homogenates and 
plasma samples, ammonium sulfamate (30 mM) in 0.9% NaCl was added to 
remove endogenous nitrite. 100 pmol [15N]-GSNO, synthesized by S-nitrosylation 
of GSH with acidified [15N]-NaNO2 (Dr. Glaser, Basle, Switzerland), was used as 
internal standard. Proteins were precipitated with 30 mM ammonium sulfamate 
and 10% trichloroacetic acid (TCA) in water and the precipitate was centrifuged at 
20,000g for 10 min at 5 ºC. The supernatants were neutralized with 4 M 
dipotassium hydrogenphosphate to pH 6.0, mixed with 1 M borate buffer to final 
pH 7.5-8.0 and derivatized for 1 min with 15.5 mM 9-fluorenylmethyl chloroformate 
(FMOCCl; Fluka, Buchs, Switzerland) in acetone at room temperature. The excess 
of FMOCCl was removed by extracting with 2 ml n-pentane.  
The FMOC-GSNO in the aqueous phase was analyzed by the LC-MS / MS 
system (analytical instrumentation as above) under an elution gradient of water / 
acetonitrile (95/5, v/v) containing 0.1% formic acid against water / acetronitrile / 
methanol (5/30/65, v/v) containing 0.1% formic acid. The flow rate was 0.3 ml min-
1. The capillary temperature was kept at 250°C, the electrospray voltage at 5 kV 
(negative ionization). The sheath gas pressure was held at 60 psi, the collision gas 
(argon) pressure at 1.30 mTorr, respectively. Standard curves for GSNO in plasma 
were linear with a correlation coefficient of <0.999. Coefficients of variation for the 
LC-MS assay were <6%. The concentrations of GSNO in brain homogenates were 
determined using the standard addition method. Tissue-to-plasma concentration 
ratios were calculated and expressed as pmol g-1 (tissue) per pmol µl-1 (plasma). 
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Effects of ABCC1 deactivation on ischemic brain injury 
The protocol of the drug efficacy studies is summarized in Supplementary Figure 
1. Two different ABCC1 deactivation strategies were used in mice subjected to 30 
or 90 min MCA occlusion, namely pharmacological inhibition with MK571 and 
genetic abcc1-/-. Animals undergoing 30 min MCA occlusion were intraperitoneally 
treated with vehicle (0.9 % NaCl) or MK571 (10 mg kg-1 body weight, as above) 
immediately after reperfusion and at 24 and 48 h after stroke. Always 60 min later, 
either vehicle (0.9 % NaCl), 17βEG (2, 5, 10 or 50 mg kg-1 body weight, as above) 
or GSNO (0.2, 0.5, 1 or 5 mg kg-1 body weight, as above) were intraperitoneally 
applied (n = 7-8 animals per group). Animals were sacrificed 72 h after reperfusion 
onset. Mice subjected to 90 min of MCA occlusion were intraperitoneally treated 
with either vehicle or MK571 (10 mg kg-1 body weight, as above) immediately after 
reperfusion, 10 min later followed by vehicle, 17βEG (2 or 10 mg kg-1 body weight, 
as above) or GSNO (0.2 or 1 mg kg-1 body weight, as above) (n = 6-8 animals per 
group). These animals were killed 24 h following stroke. 
 
Analysis of histological brain injury 
Brain sections from the level of the mid-striatum (bregma 0.0 mm) of animals 
submitted to 30 min MCA occlusion were fixed with 4% paraformaldehyde in 0.1 M 
PBS and stained by TUNEL using a commercially available kit (Roche, Basle, 
Switzerland). In these sections, DNA fragmented cells were counted in blinded 
manner in six random ROI in the striatum (1 mm apart), and six random ROI in the 
cortex (600 µm apart), each measuring 62,500 µm2. These ROI were chosen as 
30 min MCA occlusion usually leads to disseminate neuronal damage in the 
mouse striatum (Wang et al., 2005; Spudich et al., 2006), which may expand into 
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the cortex under conditions of exacerbated brain injury. In fact, exclusively striatal 
DNA fragmentation was seen in our present studies in case of most vehicle 
treated or 17βEG treated animals, whereas GSNO delivered at doses of 1 or 5 mg 
kg-1 reproducibly resulted also in cortical cell death. Animals subjected to 90 min 
MCA occlusion were analyzed by staining a total of four sections from equidistant 
brain levels, 2 mm apart (starting from the rostral pole of the striatum: bregma +2.0 
mm, followed by sections at levels bregma 0.0, -2.0 and -4.0 mm) with cresyl 
violet. Brain infarcts were outlined on these sections by delineating non-lesioned 
tissue in both hemispheres, thereby determining edema-corrected infarct areas, 
and subsequently calculating infarct volumes (Wang et al., 2005; Kilic et al., 2006). 
 
Statistics 
Results are presented as means ± s.d. Data were analyzed by one-way ANOVA 
followed by least significant differences (LSD) tests (comparisons between ≥3 
independent groups), repeated measurement ANOVA (comparisons between ≥4 
groups including within-subject comparisons), two-way ANOVA (comparisons 
between 4 independent groups elucidating drug interactions) or unpaired two-
tailed t-tests (comparisons between 2 groups), using SPSS for Windows 12.0.1. In 
case of multiple comparisons being made, significance levels were adapted using 
Bonferroni corrections.  P values less than 0.05 were considered significant. 
 
Results 
Distribution of ABCC1 in the brain and in peripheral tissues  
 
In immunohistochemistries we observed that ABCC1 is expressed on the brain 
capillary endothelium of C57Bl6/j and FVB mice, where ABCC1 was almost 
exclusively found on the abluminal surface (Fig. 1). On the other hand, ABCC1 
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was undetectable on neurons or glial cells throughout the brain (Fig. 1). Thus, 
ABCC1 expression in the brain differed from peripheral tissues, where ABCC1 
immunoreactivity was noticed on parenchymal cells and - in case of spleen and 
testis - vascular staining was faint (Fig. 2).  
 In the brain, ABCC1 levels were mildly reduced in response to focal cerebral 
ischemia (Fig. 1). Western blots using enriched brain microvessel fractions 
revealed that ABCC1 expression decreased at 3 h and partly recovered within 24 
to 72 h after stroke (Fig. 3). 
 
Effect of ABCC1 inhibition on tissue accumulation of 17βEG and GSNO 
To analyze how ABCC1 influences drug accumulation after stroke, we blocked 
ABCC1 in C57Bl6/j mice with MK571 (10 mg kg-1) and concomitantly delivered the 
ABCC1 substrates 17βEG (10 mg kg-1) or GSNO (1 mg kg-1). Notably, ABCC1 
deactivation decreased the brain-to-plasma concentration ratio of 17βEG and 
GSNO both in the ischemic and non-ischemic tissue by more than two orders of 
magnitude (P < 0.001; Fig. 4), as shown by LC-MS. 
 Following 17βEG delivery, the brain content not only of 17βE’s 17β-D-
glucuronide, but also its deglucuronidated parent compound 17βE was reduced 
(Fig. 4, P < 0.05), as our LC-MS studies revealed.  
 ABCC1’s transport function in the brain differed from the liver and testis, 
where ABCC1 deactivation mildly increased 17βEG and - in case of liver - also 
17βE levels (P < 0.05; Table). In the spleen, 17βEG and 17βE levels were not 
influenced by MK571 (Table). 
 Blood levels of 17βEG and GSNO remained unchanged after ABCC1 
deactivation (Fig. 4). Blood levels of 17βE were low in both groups 
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(log10[concentration(pmol ml-1)]: 0.32 ± 0.62 vs. 1.10 ± 1.32 in vehicle vs. MK571-
treated mice).  
 
Effect of ABCC1 inhibition on survival effects of 17βEG and GSNO 
To clarify whether ABCC1 inhibition attenuates the survival effects of 17βEG and 
GSNO, we again deactivated ABCC1 in ischemic C57Bl6/j mice with MK571 and 
subsequently applied both drugs at various dosages. Experiments in animals 
submitted to 30 or 90 min MCA occlusion consistently showed attenuation both of 
17βEG neuroprotection and GSNO neurotoxicity following ABCC1 blockade (Figs. 
5, 6). As such, drug effects were almost abolished even at doses ten times above 
the therapeutic threshold (Figs. 5, 6).  
 To evaluate the specificity of our pharmacological observations, we 
subsequently examined the effects of 17βEG and GSNO in abcc1-/- mice produced 
on a FVB background. Blunted drug responses in abcc1-/- as compared with 
abcc1+/+ animals confirmed that the changes noticed after pharmacological 
transporter blockade were indeed linked to ABCC1 (Fig. 5).  
 In abcc1-/- mice, expression patterns of ABCB1, ABCC2, ABCC3 and ABCC5 
were identical to abcc1+/+ animals. Thus, ABCC2 and ABCC3, which also bind 
glucuronidated and/or glutathionized compounds (Löscher and Potschka, 2005), 
were absent and ABCB1 and ABCC5, which bind unconjugated but not conjugated 
molecules (Löscher and Potschka, 2005), were expressed at similar levels in both 
mouse lines (Suppl. Fig. 2).  
 
Discussion 
While the role of ABC transporters in drug elimination is well-established in many 
diseases, including stroke, epilepsy and brain cancer (Löscher and Potschka, 
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2005; Hermann et al., 2006), we for the first time provide evidence that an ABC 
transporter, ABCC1, actively promotes the accumulation and efficacy of 
pharmacological compounds in the ischemic brain. As such, the profoundly 
reduced tissue levels, which were more than hundredfold below control conditions 
when ABCC1 was deactivated, suggest that drug accumulation may be more 
strongly than previously thought an active process. As ABCC1 is a broad-
spectrum transporter, which binds a large variety of chemically unrelated 
substrates (Hermann and Bassetti, 2007), ABCC1 might offer itself as vehicle for 
drug delivery purposes. It is noteworthy that ABCC1 was still functional in the brain 
after ischemia, despite the fact that ABCC1 levels were mildly reduced. ABCC1’s 
retained functionality exemplifies its importance for drug biodistribution processes. 
 
Transport activity attributed to expression pattern   
ABCC1’s role at the BBB profoundly differs from the liver, spleen and testis. In the 
liver and testis, ABCC1 deactivation mildly increased levels of the ABCC1 
substrate 17βEG, just opposite to our findings in the brain. The specificities of 
pharmacological transport are attributed to differences in ABCC1 expression. As 
such, the abluminal endothelial expression of ABCC1 at the polarized BBB 
explains why the transporter promotes molecular uptake into the brain. On the 
other hand, parenchymal expression provides a rationale for ABCC1’s role in drug 
removal in peripheral tissues. On the cellular level, ABC transporters act as ATP-
dependent efflux pumps carrying drugs from the intracellular towards extracellular 
space. This directional transport was recently confirmed using crystal structures of 
ABC transporter molecules (Murakami et al., 2006). It was also shown for ABCC1 
in in vitro studies, in which ABCC1 was deactivated by pharmacological blockade, 
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small-interfering RNA or genetic knockout (Regina et al., 1998; Seetharaman et 
al., 1998; Müller et al., 2005).  
 ABCC1 expression in the brain had been a matter of debate previously. In 
vitro studies with rodent, bovine and human brain microvessels reported ABCC1 
expression on endothelial cells and astrocytes (Regina et al., 1998; Seetharaman 
et al., 1998; Berezowski et al., 2004). Importantly, ABCC1 levels increased with 
cell culturing, suggesting that its role in vivo differs from in vitro (Regina et al., 
1998; Seetharaman et al., 1998). ABCC1 has been observed on astrocytes in 
models of drug-refractory epilepsy (Dombrowski et al., 2001; van Vliet et al., 
2005). In drug-refractory epilepsy, several ABC transporters are induced (van Vliet 
et al., 2005). As such, this condition is not representative for the healthy brain. In 
healthy rodents, ABCC1 was found exclusively on brain capillaries but not 
astrocytes (Soontornmalai et al., 2006). Our here presented data after ischemia 
confirm these findings. In Western blots, we have never been able to detect 
ABCC1 in whole brain homogenates (not shown), but only in capillary-enriched 
fractions. We conclude that ABCC1 is not expressed in the brain parenchyma to 
relevant extent.  
 We did not observe ABCC2 expression on brain capillaries of FVB mice. The 
lack of ABCC2 expression is in line with previous studies, which also did not 
localize ABCC2 on brain capillaries in this mouse line (Soontornmalai et al., 2006). 
As such, ABCC2’s expression in FVB mice differs from C57Bl6/j mice 
(Soontornmalai et al., 2006) and rats (van Vliet et al., 2005), where ABCC2 
expression was previously reported.  
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Choice of ABCC1 substrates 
To evaluate the functionality of ABCC1, we chose two compounds, 17βEG and 
GSNO, which are known substrates of ABCC1 but not ABCB1 and which we 
considered both to be neuroprotective after stroke. In case of 17βE, survival-
promoting actions are well established after focal cerebral ischemia (Yang et al., 
2000; Rau et al., 2003). In case of GSNO, neuroprotective effects had also been 
described in a rat model of ischemic stroke (Khan et al., 2005). We were surprised 
that GSNO exacerbated brain injury in mice after MCA occlusion. GSNO acts as 
NO donor, which promotes the reactivity of brain arterioles, but exacerbates 
neuronal injury via free radical formation (Dalkara and Moskowitz, 1994; Chan, 
2001). Neuronal effects most likely explain the injury-aggravating effect of GSNO. 
Since we used 17βEG and GSNO as model compounds and were not interested 
in their mechanisms of action, the fact that GSNO increased ischemic injury was of 
minor importance for our studies.  
 
Considerations regarding earlier biodistribution studies  
Previous reports had not been unambiguous about the role of ABCC1 in drug 
distribution. As such, an involvement of ABCC1 in drug elimination had been 
suggested following 17βEG and GSNO delivery in some (Nishino et al., 1999; 
Sugiyama et al., 2003), but not other (Cisternino et al., 2003; Lee et al., 2004) 
studies. Unfortunately, earlier studies strongly focused on ABCC1’s role at the 
luminal endothelial membrane. As such, intracerebral (Sugiyama et al., 2003) or 
intracerebroventricular (Nishino et al., 1999; Lee et al., 2004) drug infusions were 
mostly used. Moreover, autoradiographic techniques were applied for 17βEG and 
GSNO measurement (Nishino et al., 1999; Sugiyama et al., 2003; Cisternino et al., 
2003; Lee et al., 2004), which did not distinguish 17βEG and GSNO from 17βE 
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and glutathione, to which the molecules were cleaved (17βEG: shown here; 
GSNO: see Lee et al., 2004). As a consequence, not the delivered parent 
compounds, but their metabolites were measured in the brain tissue. 
Methodological limitations explain the earlier non-specific findings. 
 
Physiological role of ABCC1 at the BBB 
The substrate affinity to glucuronidated, glutathionized and sulfated compounds is 
a characteristic feature of ABCC1 (Hermann and Bassetti, 2007). These 
compounds are so-called phase II degradation products, which have been 
metabolized in order to be excreted via the kidneys. The question arises to which 
purpose an ABC transporter accumulates conjugated molecules in the brain. Our 
observation that 17βEG uptake went along with elevated 17βE levels sheds light 
on this issue, indicating that 17βEG was deglucuronidated, most likely by β-
glucuronidase (Brooks et al., 2002). β-glucuronidase is a lysosomal hydrolase 
constitutively expressed in the brain that is deficient in mucopolysaccharidosis VII 
(Brooks et al., 2002), a neurodegenerative disorder. Our finding of 17βEG 
deglucuronidation suggests that ABCC1 enables 17βE recycling, offering the brain 
the possibility to regenerate conjugated molecules. 
 ABCC1 shares its affinity to phase II degradation products with transporters 
of the solute carrier-21 family, which are involved in drug uptake into capillary cells 
(Meier and Stieger, 2002; Hagenbuch and Meier, 2004). 17βEG and GSNO are 
known substrates of solute carrier-21 transporters, namely of organic anion 
transporter (Oatp)1a4, which is expressed at the luminal membrane of brain 
capillary cells (Gao et al., 1999). That ABCC1 accumulated drugs in the brain 
tissue implies that solute carriers were functional. The role of solute carriers in 
drug biodistribution will deserve additional attention in the future. 
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Implications of abluminal ABC transporters for drug development 
That an active transporter contributes to drug accumulation in the brain following 
stroke has important clinical implications. As such, the brain access of drugs may 
markedly be improved by chemical modifications resulting in increased ABCC1 
affinity. In view of ABCC1’s strong affinity to conjugated molecules, 
glucuronidation, glutathionization or sulfatation may render drugs able to pass the 
BBB. Drug – protein interactions have gained huge interest in drug development 
recently. As such, crystal structures have offered new insights into the kinetics of 
drug binding with ABC transporters (Murakami et al., 2006). Based on our data, 
crystal structures might allow the selection of new generations of drugs that bind to 
abluminal, but lack interactions with luminal ABC transporters. This might potently 
increase brain accumulation and drug efficacy, and enhance the overall success of 
pharmacological therapies.  
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Table Tissue-to-plasma concentration ratios of 17βEG and 17βE in the liver, 
spleen and testis (in pmol mg-1 per pmol µl-1). 
 
17βEG 17βE  
Liver spleen testis liver Spleen testis 
17βEG 6.01 
±2.03 
1.35 
±0.45 
0.60 
±0.15 
251.98 
±134.40 
19.46 
±9.74 
5.57 
±2.11 
MK571/ 
17βEG 
32.49 
±25.90* 
1.04 
±0.25 
0.89 
±0.29* 
810.00 
±333.40* 
23.66 
±12.54 
9.83 
±5.28 
 
*P < 0.05 compared with animals receiving 17βEG only (unpaired t-tests).  
n = 7 animals per group. 
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Legends to Figures 
Fig. 1 ABCC1 is expressed on brain capillaries on the abluminal surface between 
the luminal membrane (CD31) and astrocytic endfeet (GFAP). Confocal laser 
scanning microphotographs showing ABCC1 in ischemic vessels 3 h after 30 min 
MCA occlusion (A, B). Note the absence of ABCC1 in the brain parenchyma, i.e., 
on neurons (NeuN) and astrocytes (GFAP). The quantitative analysis of vessel 
densities in the cortex and striatum of mice submitted to 30 min (C) and 90 min (D) 
MCA occlusion reveals reduced ABCC1 levels at 3 h following stroke. Data from 
C57Bl6/j mice are shown. Data are means ± s.d. (n = 5 per group, repeated 
measurement ANOVA, time effects are shown, and t-tests). *P < 0.05 / **P < 0.01 
compared with contralateral sham. Bar, 30 µm. 
 
Fig. 2 ABCC1 distribution in the liver, spleen and testis differs from the brain. 
Immunohistochemistries revealing abundant ABCC1 expression (A) in the liver on 
CD31- hepatocytes (hc) and - slightly less intense - on endothelial cells of a 
central vein (cv), (B) in the spleen on CD31- cells of the white pulp (wp), but not on 
CD31+ central arteries (ca) and CD31- red pulp (rp), and (C) in the testis on 
spermatids (sp) and seminiferous tubules (st). Sections from C57Bl6/j mice are 
shown. Bar, 100 µm (left) / 50 µm (right). 
 
Fig. 3 ABCC1 expression decreases in response to focal cerebral ischemia. 
Western blot analysis exhibiting the ~190 kDa ABCC1 protein in enriched 
microvessel fractions of brains from sham-animals and animals submitted to 30 
min (A) or 90 min (B) MCA occlusion, followed by 3 - 72 h reperfusion. Note that 
ABCC1 levels declines already 3 h after ischemia both in ischemic and 
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contralateral injury-remote tissue, recovering partly within 72 h after 30 min MCA 
occlusion. Data were analyzed densitometrically and corrected for protein loading 
assessed on β-actin blots. Control experiments, in which the primary antibody was 
omitted, did not reveal any signal (not shown). Capillary extracts from C57Bl6/j 
mice were used. Values are means ± s.d. (n = 3 different blots per group). Data 
were evaluated by repeated measurement ANOVA (time effects shown) and t-
tests. *P < 0.05 / **P < 0.01 compared with contralateral sham. 
 
Fig. 4 Pharmacological inhibition of ABCC1 with MK571 dramatically reduces the 
brain accumulation of 17βEG and GSNO in C57Bl6/j mice. Plasma concentrations 
(A, D) and brain-to-plasma concentration ratios (B, D, E) for 17βEG, its parent 
17βE and GSNO, analyzed by LC-MS in mice submitted to focal cerebral ischemia 
induced by 30 min MCA occlusion. Data are means ± s.d. (n = 5-7 per group [A, 
B], n = 4 per group [C, D]). Repeated measurement ANOVA and t-tests (drug 
effects are shown). *P < 0.05 / **P < 0.01 compared with animals receiving 17βEG 
(10 mg kg-1) or GSNO (1 mg kg-1) only. 
 
Fig. 5 Deactivation of ABCC1 abolishes 17βEG’s neuroprotective and GSNO’s 
neurotoxic effects after focal cerebral ischemia induced by 30 min MCA occlusion. 
Laser Doppler flow (LDF) measurements during and after ischemia (A, C) and 
disseminate cell death evaluated by terminal transferase biotinylated-dUTP nick 
end labeling (TUNEL; green fluorescence) 72 h after reperfusion (B, D). Note the 
absence of blood flow changes between groups (A, C). Furthermore note that 
deactivation of ABCC1 by pharmacological blockade in C57Bl6/j mice and abcc1-/- 
in FVB mice almost completely reverses drug effects on ischemic injury (B, D). 
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Representative microphotographs for TUNEL stainings showing DNA-fragmented 
cells in the striatum are also presented. Data are means ± s.d. (n = 7-8 per group). 
One-way ANOVA and LSD tests (≥3 groups), two-tailed t-tests (B, D: 2 groups), 
two-way ANOVA (B, D: 2x2 comparisons, drug interaction effects are shown). *P < 
0.05 / **P < 0.01 compared with vehicle-treated control mice; †P < 0.05 / ††P < 
0.01 compared with animals receiving 17βEG (10 mg kg-1) or GSNO (1 mg kg-1) 
only; §§P < 0.01 compared with abcc1+/+ mice. Bar, 120 µm. 
 
Fig. 6 Inhibition of ABCC1 with MK571 reverses 17βEG’s neuroprotective and 
GSNO’s neurotoxic effects after focal cerebral ischemia induced by 90 min MCA 
occlusion. LDF during and after ischemia (A, D), infarct volume (B, E) and infarct 
areas at various rostrocaudal brain levels (C, F) assessed by cresyl violet staining 
24 hours after reperfusion. Note again the absence of blood flow changes between 
groups (A, D). Note again that ABCC1 deactivation (here in C57Bl6/j animals) 
abolishes 17βEG’s and GSNO’s effects on infarct size (B, C, E, F). Data are 
means ± s.d. (n = 6-8 animals per group). One-way ANOVA and LSD tests (A-F), 
two-way ANOVA (B, E: 2x2 comparisons, drug interaction effects are shown). *P < 
0.05 / **P < 0.01 compared with vehicle-treated mice; †P < 0.05 / ††P < 0.01 
compared with animals receiving 17βEG (10 mg kg-1) or GSNO (1 mg kg-1) only. 
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Legends to Supplementary Figures 
Suppl. Fig. 1 Protocol of MK571, 17βEG and GSNO delivery used in order to 
study the functionality of the ABCC1 transporter in the ischemic brain (drug 
efficacy studies). Animals were submitted to 30 or 90 min MCA occlusion, followed 
by 72 or 24 h of reperfusion. Immediately after the stroke, either vehicle or MK571 
were applied at a dosage of 10 mg kg-1. 60 min (30 min MCA occlusion) or 10 min 
(90 min) later, either vehicle or 17βEG (2, 5, 10 or 50 mg kg-1), or vehicle or GSNO 
(0.2, 0.5, 1 or 5 mg kg-1) were administered. In case of 30 min MCA occlusion, 
drug delivery was repeated at 24 and 48 h after stroke. For abcc1-/- studies an 
almost identical protocol was used, except that MK571 was omitted. 
 
Suppl. Fig. 2 ABCB1, ABCC2, ABCC3 and ABCC5 expression levels in the brain 
do not differ between abcc1+/+ and abcc1-/- mouse lines produced on a FVB 
background. Immunohistochemistries showing expression of ABCB1 and ABCC5, 
but not ABCC2 and ABCC3 on CD31+ capillaries. Note the absence of ABCC1 
immunoreactivity in abcc1-/- animals. Bar, 20 µm. 
 
